A double-blind split-face randomized controlled trial of the efficacy of 2% Curcuma aeruginosa Roxb. extract-containing cream compared with 2% ketoconazole cream in facial seborrheic dermatitis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210416002

Enrollment

Registered

2021-04-16

Start date

2021-04-16

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

facial seborrheic dermatitis facial seborrheic dermatitis, 2% Curcuma aeruginosa, 2% Ketoconazole

Interventions

BID, for 4 weeks, apply on half of the face, BID, for 4 weeks, apply on another half of the face

Experimental Drug,Active Comparator Drug

2% Curcuma aeruginosa Roxb. extract-containing cream,2% ketoconazole cream

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: facial seborrheic dermatitis

Exclusion criteria

Exclusion criteria: 1. Subjects with any untreated or uncontrolled dermatitis on the face, 2. severe co-morbidity, 3. suspected allergy to any study medication, 4. pregnant and lactating women, 5. Subjects who used topical agents(except bland emollients) on the face < 2 weeks before study was initiated, 6. Subjects who had used systemic antifungal agents for > 1 month

Design outcomes

Primary

Measure	Time frame
severity of facial seborrheic dermatitis at 4 weeks scoring index	—

Secondary

Measure	Time frame
skin hydration, sebum week 2, 4 corneometer, sebumeter	—

Countries

Thailand

Contacts

Public ContactPanlop Chakkavittumrong

Department of Internal Medicine, Division of Dermatology, Faculty of Medicine, Thammasat University

panlop078@gmail.com66909894056

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026